Julie M. Vose, MD, MBA
Julie M. Vose, MD is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center in Omaha, Nebraska. Dr Vose received her medical degree, completed her residency in Internal Medicine, served as Chief Resident, and completed a Fellowship in Hematology/Oncology at the University of Nebraska Medical Center. Dr Vose also completed a sabbatical at Stanford University. She also completed an MBA in Health Administration through the University of Colorado Business School.
Dr. Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin’s lymphoma (NHL) and Hodgkin lymphoma (HL) by developing a focused translational research program evaluating novel therapies such as radiolabeled monoclonal antibodies, idiotype vaccine therapies, pathway directed agents and stem cell transplantation. Dr Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide. In addition, her funding record and publications in NHL therapy and transplantation research have added substantially to the research and knowledge base for the therapy of lymphoma. She is currently the Co-Chair for the National Cancer Institute Lymphoma Sub-Committee, a member of the FDA Oncologic Drug Advisory Committee, and 2014-15 President elect for the American Society of Clinical Oncology (ASCO).